The company plans to file in the third quarter of 2013. AcelRx tested its ARX-01 Sufentanil NanoTab patient-controlled analgesia system against intravenous PCA with morphine on 359 adult patients. Initial data shows the NanoTab to be significantly better than intravenous morphine.
While intravenous morphine PCAs are common in hospitals, morphine can cause nausea, vomiting and other opioid-related side effects. It also carries a higher risk of addiction. Rather than morphine, the NanoTab administers sufentanil, another opioid with fewer side effects.
More Articles on Anesthesia:
Medication Safety Initiative Created by CareFusion
Recall Issued for Mindray Anesthesia Delivery System
4 Skills to Look for When Including Anesthesia Groups in an ACO
